Q-omics provides the consensus-scored TOR1BP1 profile across patient tissues and cancer cell-line models. TOR1BP1 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TOR1BP1 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, TOR1BP1 RNA expression shows 6,636 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, and STAD as cancer lineages where TOR1BP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TOR1BP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TOR1BP1 survival associations across molecular data types. TOR1BP1 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TOR1BP1 RNA expression–survival associations across cancer types. High TOR1BP1 expression shows unfavorable associations in KIRC, PAAD, CHOL, ACC and LIHC, but favorable associations in LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify KIRC as the clearest survival context for TOR1BP1 RNA expression.
This table summarizes TOR1BP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TOR1BP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TOR1BP1 shows lower tumor expression in KIRC and KICH and higher tumor expression in BRCA, HNSC and STAD. The KIRC box plot shows higher TOR1BP1 RNA expression in normal versus tumor tissue (log2 FC = −0.024, t-test p = .001).
This table shows molecular features associated with TOR1BP1 in patient tissues and cancer cell lines. In patient samples, TOR1BP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
